The future of health is not about managing
decline—it is about restoring biology. Biology Beyond invests in the people, technologies, and businesses transforming healthcare from treating disease to restoring human function and advancing a new era of regenerative, preventative and optimised health. When we restore healthier biological function, longevity and health span become the natural consequence—not the destination.
For example: Stempheresis®.
Biology Beyond exists to remove barriers to regenerative healthcare by connecting capital with world-leading clinicians, researchers, and
healthcare innovators.
Through strategic investment, the Fund seeks to expand access to regenerative medicine across developed and emerging markets, improving patient outcomes, and redefining the future of healthcare.
To become the world’s leading investment platform for regenerative health, enabling equitable access to advanced therapies while delivering sustainable long-term returns for investors.
Healthcare systems around the world continue to focus on managing disease after it occurs. Biology Beyond believes the future of healthcare lies in restoring biological function rather than simply treating symptoms. Regenerative medicine, including Stempheresis® therapies, tissue engineering, advanced diagnostics, and personalised medicine, is transforming how chronic disease, ageing, and degenerative conditions are managed.
However, access remains limited. The sector remains fragmented.
Investment is disconnected. Many patients cannot access potentially
life-changing therapies because of geography, affordability or limited clinical capacity. Biology Beyond has been created to solve this problem.
Collectively, these assets create diversified revenue streams while strengthening the broader regenerative healthcare ecosystem.
The Financial Dividend is focused on delivering sustainable long-term investment performance through ownership in one of the world’s leading regenerative health ecosystems.
The Biology Beyond Foundation will serve as the philanthropic arm of the Fund.
Its purpose is to ensure that advances in regenerative medicine benefit society broadly, not only those with the financial means to access premium healthcare.
The Foundation will seek to:
Biology Beyond seeks to deliver attractive, long-term financial performance through a globally diversified portfolio of regenerative health assets.
Exposure to a diversified portfolio of clinics, regenerative medicine, medical technologies, diagnostics, AI platforms, and healthcare businesses.
Proudly listed on the BT Asset Hub, providing investors with access to institutional-quality regenerative health investments.
The BXB Human Legacy™ is what makes Biology Beyond fundamentally different.
Every investment delivers lasting value beyond financial returns by creating benefits for both the investor and the wider community.
Investors become members of the Biology Beyond ecosystem, receiving exclusive BXB Regenerative Credits™ that can be redeemed across participating clinics and healthcare partners for approved regenerative health services.
Membership provides privileged access to world-leading clinicians, therapies and wellness programs while encouraging proactive investment in personal health and wellbeing.
At the same time, every investment contributes directly to the Biology Beyond Foundation.
Through the allocation of BXB Foundation Credits™, the Foundation provides regenerative treatments and healthcare support to disadvantaged patients, underserved communities and individuals who would otherwise have limited access to these life-changing therapies.
As the Fund grows, so too does its capacity to improve lives.
Dr. Torbjörn Ogéus is an internationally recognised scientist, clinician, and pioneer in regenerative medicine, serving as Head Scientific Advisor to the Biology Beyond Board. As Founder and Lead Clinician of SLS (Stockholms Led- & Smärtspecialist) in Stockholm, he has become a global leader in stem cell and exosome therapies, delivering more than 15,000 regenerative treatments over a distinguished clinical career.
Holding four master’s degrees and the author of 15 peer-reviewed scientific publications, Dr. Ogéus has contributed significantly to advancing regenerative medicine. His research includes pioneering studies demonstrating increased joint space following stem cell treatment and the discovery of methods to activate pluripotent stem cells from adult blood, expanding the future potential of regenerative therapies.
A former professional athlete whose career was cut short by osteoarthritis at the age of 30, Dr. Ogéus turned personal adversity into scientific innovation. Rather than accepting conventional treatment, he developed regenerative approaches that restored his own joint function: an experience that continues to shape his commitment to advancing patient care.
As Head Scientific Advisor, Dr. Ogéus provides strategic scientific leadership to Biology Beyond, ensuring the Fund remains at the forefront of regenerative health, clinical innovation, and evidence-based medicine.
Markus Klotz is an internationally recognised strategist, researcher and innovator in therapeutic apheresis and regenerative medicine, serving as Head Strategist to the Biology Beyond Board. As Co-Founder of Elysium Institut Switzerland, he leads the strategic development of advanced regenerative healthcare facilities, medical technologies and next-generation treatment models.
Markus’s journey into regenerative medicine followed his own recovery from severe Long COVID through H.E.L.P. Apheresis and multimodal therapy under the care of Dr. Beate Jaeger in Germany. Inspired by his recovery, he founded the Apheresis Center Larnaca in 2022, recognised as the world’s first purpose-built Long COVID clinic, pioneering integrated treatment protocols combining advanced apheresis, diagnostics, nutritional medicine and personalised patient care.
A member of the RAPID Research Team, Markus collaborates with leading scientists, clinicians and researchers to advance understanding of immune dysfunction, microcirculation and regenerative therapies. His work has been featured internationally, including the ARTE documentary on Long COVID.
As Head Strategist, Markus is leading the expansion of Biology Beyond’s global regenerative health ecosystem, driving the development of world-class clinics, innovative medical technologies and scalable treatment platforms that support the Fund’s mission of Democratising Regenerative Health.
Caroline Macdonald is a technology entrepreneur, ecosystem builder and community leader with a distinguished career in digital innovation, platform development and strategic business growth. As Founder and CEO of Black Tie Holdings, she leads the development of the BT Asset Hub—the digital investment marketplace on which the Biology Beyond Fund is proudly listed, enabling broader investor participation in the future of regenerative health.
Caroline’s passion for Biology Beyond is deeply personal. Living with Retinitis Pigmentosa (RP), a progressive inherited retinal degenerative disease, she understands the urgent need for innovative regenerative therapies and equitable access to emerging treatments.
As Chairwoman, Caroline is committed to Biology Beyond’s mission of Democratising Regenerative Health, leveraging technology, investment and global collaboration to connect capital with world-leading regenerative healthcare businesses. She also champions the Biology Beyond Foundation, ensuring every investment contributes to expanding access to life-changing regenerative therapies for disadvantaged patients and underserved communities worldwide.
Michael Kelly is the Founder and Visionary behind Biology Beyond, bringing more than 25 years of experience across construction, property development, real estate, investment strategy and business creation. Throughout his career, he has facilitated transactions ranging from residential investments to institutional development projects exceeding $100 million, building a reputation for identifying strategic opportunities and creating long-term value.
Michael has played a key role in the development of innovative investment platforms, culminating in Biology Beyond—his most significant and purpose-driven venture.
Michael’s vision for Biology Beyond was born not only from business, but from personal experience. After serving ten years as a firefighter, exposure to toxic chemicals resulted in chronic health challenges that led him on a 25-year journey exploring regenerative medicine, advanced therapies and emerging healthcare technologies. This pursuit introduced him to world-leading experts in regenerative health and ultimately inspired the creation of Biology Beyond.
Today, Michael is committed to building a globally connected regenerative health ecosystem that unites clinics, technology, real estate & investment and research to democratise access to regenerative healthcare. His vision is to ensure that life-changing therapies become accessible to communities worldwide, while creating sustainable value for investors and meaningful impact through the Biology Beyond Foundation.
Lee Oakey is an experienced entrepreneur, business builder and strategic operator with more than 40 years of experience across financial services, real estate, healthcare and investment markets in the UK, USA and Australia.
Throughout his career, Lee has specialised in taking opportunities from concept through to commercial execution—building businesses from the ground up, establishing operational structures across multiple jurisdictions, developing supply chains and creating scalable, revenue-generating enterprises.
His experience has frequently placed him at the forefront of emerging and underdeveloped markets, where success requires the ability to identify opportunity, assess risk, build the right commercial framework and execute decisively.
This experience brings an important commercial perspective to Biology Beyond as it builds a globally diversified regenerative health ecosystem spanning clinics, advanced therapies, medical technologies, research and healthcare businesses.
Lee’s focus is on helping translate the extraordinary innovation occurring within regenerative health into commercially sustainable businesses capable of operating and expanding at scale.
As Strategic Advisor, Lee supports Biology Beyond in evaluating opportunities, developing commercial structures and building the partnerships and operational foundations required to expand its global ecosystem.
His approach aligns closely with the Biology Beyond mission: bringing together innovation, investment and practical execution to help make the next generation of regenerative healthcare more accessible around the world.
